Formycon AG (0W4N.L)
| Previous close | 79.43 |
| Open | 79.50 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 79.50 - 79.50 |
| 52-week range | 79.50 - 79.50 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 669.015M |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.30 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Aflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 in Phase III Study
EQS-News: Formycon AG / Key word(s): Study results/StudyAflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 in Phase III Study 06.02.2023 / 07:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Press Release // February 6, 2023Aflibercept Biosimilar Candidate FYB203 shows comparable efficacy to the reference product Eylea®1 in Phase III Study MAGELLAN-AMD study demonstrates the comparable efficacy of FYB203 to the refer
- EQS Group
Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)
EQS-News: Formycon AG / Key word(s): Agreement/AllianceFormycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab) 02.02.2023 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Press Release February 2, 2023Formycon and Fresenius Kabi conclude global commercialization partnership for FYB202, a biosimilar candidate to Stelara®1 (ustekinumab)Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN:
- EQS Group
Formycon AG announces result of private placement and sets placement price for the new shares from the capital increase
Formycon AG / Key word(s): Capital Increase/Corporate ActionFormycon AG announces result of private placement and sets placement price for the new shares from the capital increase02-Feb-2023 / 07:30 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, I
